104 related articles for article (PubMed ID: 28921512)
1. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
Van Sebille YZA; Gibson RJ; Wardill HR; Ball IA; Keefe DMK; Bowen JM
Int J Cancer; 2018 Jan; 142(2):369-380. PubMed ID: 28921512
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
[TBL] [Abstract][Full Text] [Related]
3. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea.
Yeo QM; Crutchley R; Cottreau J; Tucker A; Garey KW
Drugs Today (Barc); 2013 Apr; 49(4):239-52. PubMed ID: 23616951
[TBL] [Abstract][Full Text] [Related]
4. Crofelemer, a novel agent for treatment of secretory diarrhea.
Crutchley RD; Miller J; Garey KW
Ann Pharmacother; 2010 May; 44(5):878-84. PubMed ID: 20388859
[TBL] [Abstract][Full Text] [Related]
5. Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons.
Chordia P; MacArthur RD
Expert Rev Gastroenterol Hepatol; 2013 Sep; 7(7):591-600. PubMed ID: 24070150
[TBL] [Abstract][Full Text] [Related]
6. Crofelemer for the treatment of secretory diarrhea.
Cottreau J; Tucker A; Crutchley R; Garey KW
Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):17-23. PubMed ID: 22149578
[TBL] [Abstract][Full Text] [Related]
7. TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea.
Wardill HR; Bowen JM; Van Sebille YZ; Secombe KR; Coller JK; Ball IA; Logan RM; Gibson RJ
Mol Cancer Ther; 2016 Nov; 15(11):2767-2779. PubMed ID: 27550942
[TBL] [Abstract][Full Text] [Related]
8. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
Macarthur RD; Hawkins TN; Brown SJ; Lamarca A; Clay PG; Barrett AC; Bortey E; Paterson C; Golden PL; Forbes WP
HIV Clin Trials; 2013; 14(6):261-73. PubMed ID: 24334179
[TBL] [Abstract][Full Text] [Related]
10. Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective.
Biswal S
Recent Pat Antiinfect Drug Discov; 2014; 9(2):136-43. PubMed ID: 25851117
[TBL] [Abstract][Full Text] [Related]
11. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels.
Tradtrantip L; Namkung W; Verkman AS
Mol Pharmacol; 2010 Jan; 77(1):69-78. PubMed ID: 19808995
[TBL] [Abstract][Full Text] [Related]
12. Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.
Frampton JE
Drugs; 2013 Jul; 73(10):1121-9. PubMed ID: 23807722
[TBL] [Abstract][Full Text] [Related]
13. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.
Patel TS; Crutchley RD; Tucker AM; Cottreau J; Garey KW
HIV AIDS (Auckl); 2013; 5():153-62. PubMed ID: 23888120
[TBL] [Abstract][Full Text] [Related]
14. The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs.
Kleindl PA; Xiong J; Hewarathna A; Mozziconacci O; Nariya MK; Fisher AC; Deeds EJ; Joshi SB; Middaugh CR; Schöneich C; Volkin DB; Forrest ML
J Pharm Sci; 2017 Nov; 106(11):3242-3256. PubMed ID: 28743606
[TBL] [Abstract][Full Text] [Related]
15. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.
Castro JG; Chin-Beckford N
Expert Rev Clin Pharmacol; 2015; 8(6):683-90. PubMed ID: 26517110
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
Mangel AW; Chaturvedi P
Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
[TBL] [Abstract][Full Text] [Related]
17. A tannic acid-based medical food, Cesinex(®), exhibits broad-spectrum antidiarrheal properties: a mechanistic and clinical study.
Ren A; Zhang W; Thomas HG; Barish A; Berry S; Kiel JS; Naren AP
Dig Dis Sci; 2012 Jan; 57(1):99-108. PubMed ID: 21748285
[TBL] [Abstract][Full Text] [Related]
18. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Jacob S; Johnson M; Roque B; Quintal L; Rugo HS; Melisko M; Chien AJ
Clin Breast Cancer; 2023 Oct; 23(7):721-728. PubMed ID: 37474374
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of zinc on rat intestinal epithelial electrogenic ion secretion: insights into its antidiarrhoeal actions.
Bzik VA; Medani M; Baird AW; Winter DC; Brayden DJ
J Pharm Pharmacol; 2012 May; 64(5):644-53. PubMed ID: 22471360
[TBL] [Abstract][Full Text] [Related]
20. Crofelemer (Fulyzaq) for antiretroviral-induced diarrhea.
Med Lett Drugs Ther; 2013 Jul; 55(1421):59-60. PubMed ID: 23863919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
